Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Major Depressive Disorder (2 trials), Essential Tremor, Post-traumatic Stress Disorder, Post Traumatic Stress Disorder, Stress Disorder, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
- Main trialPhase 2/3
- “This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.”In the company’s words, NCT04832425 on ClinicalTrials.gov
Other drugs for Major Depressive Disorder
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 5 May 2022 | A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder | |
| Phase 2Withdrawn | 30 Jun 2022 | A Clinical Trial of PRAX-114 in Participants With Essential Tremor | |
| Phase 2Completed | 15 Jul 2022 | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder | |
| Phase 2Terminated | 1 Aug 2022 | A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026